<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004886</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16992</org_study_id>
    <secondary_id>EORTC-16992</secondary_id>
    <nct_id>NCT00004886</nct_id>
  </id_info>
  <brief_title>MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase I Study to Determine the Safety of MS-209 in Combination With Docetaxel in Patients With a Solid Progressive Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of MS 209 plus docetaxel in treating&#xD;
      patients who have advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of oral MS-209 when given with docetaxel IV in&#xD;
           patients with advanced solid malignant tumors.&#xD;
&#xD;
        -  Assess the toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation, multicenter study of MS-209.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour on day 1 of a 3 week course. On day 1 of the 2nd&#xD;
      course, patients receive MS-209 orally followed by docetaxel IV over 1 hour. Treatment is&#xD;
      repeated every 3 weeks for 4-7 courses (including course with docetaxel alone). Treatment&#xD;
      continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of MS-209 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 3 of 6 patients&#xD;
      experience dose limiting toxicities.&#xD;
&#xD;
      Patients are followed every 6 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">30</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dofequidar fumarate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced malignant solid tumor&#xD;
&#xD;
               -  No gastric cancer&#xD;
&#xD;
          -  No brain involvement or leptomeningeal disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 11.2 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.4 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Normal cardiac function&#xD;
&#xD;
          -  Left ventricular ejection fraction normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No digestive disease that hampers absorption&#xD;
&#xD;
          -  No unstable systemic disease or uncontrolled infection that precludes study&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that precludes&#xD;
             compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (6 weeks if extensive)&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer drugs&#xD;
&#xD;
          -  No other concurrent investigational therapies&#xD;
&#xD;
          -  No H2-blockers, proton pump inhibitors, sucralfate or any other drug that would impair&#xD;
             absorption&#xD;
&#xD;
          -  No concurrent drugs exhibiting liver, kidney, heart or lung toxicity&#xD;
&#xD;
          -  No concurrent MDR-modulating drugs (e.g., calcium antagonists, immunosuppressives)&#xD;
&#xD;
          -  No concurrent antifungals (ketoconazole, fluconazole) or antibiotics (clarithromycin,&#xD;
             erthromycin) that interfere with MS-209 metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique Dieras, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Section Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemato-Onkologische Praxis und Tagesklinik</name>
      <address>
        <city>Munich (Muenchen)</city>
        <zip>D-80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>September 30, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Dofequidar</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

